Fieldpoint Private Securities LLC Sells 259 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

Fieldpoint Private Securities LLC decreased its position in shares of BeiGene, Ltd. (NASDAQ:BGNEGet Rating) by 59.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 180 shares of the company’s stock after selling 259 shares during the quarter. Fieldpoint Private Securities LLC’s holdings in BeiGene were worth $34,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of BGNE. Indus Capital Partners LLC grew its stake in shares of BeiGene by 563.0% during the 4th quarter. Indus Capital Partners LLC now owns 106,153 shares of the company’s stock worth $28,760,000 after acquiring an additional 90,143 shares during the period. Bridgewater Associates LP raised its holdings in shares of BeiGene by 30.4% in the 4th quarter. Bridgewater Associates LP now owns 229,483 shares of the company’s stock valued at $62,174,000 after acquiring an additional 53,560 shares in the last quarter. Segantii Capital Management Ltd purchased a new position in shares of BeiGene during the 4th quarter valued at about $12,298,000. BSN Capital Partners Ltd purchased a new position in shares of BeiGene during the 4th quarter valued at about $11,758,000. Finally, UBS Group AG raised its holdings in shares of BeiGene by 74.1% during the 3rd quarter. UBS Group AG now owns 86,578 shares of the company’s stock valued at $31,428,000 after buying an additional 36,837 shares in the last quarter.

Several research firms recently issued reports on BGNE. Morgan Stanley raised their price target on BeiGene from $330.00 to $338.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 12th. StockNews.com lowered BeiGene from a “hold” rating to a “sell” rating in a research report on Thursday, June 16th. Finally, SVB Leerink lowered BeiGene from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $300.00 to $177.00 in a research report on Thursday, March 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $315.33.

In related news, insider Lai Wang sold 445 shares of BeiGene stock in a transaction that occurred on Friday, June 17th. The stock was sold at an average price of $139.40, for a total transaction of $62,033.00. Following the sale, the insider now directly owns 723 shares in the company, valued at $100,786.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Xiaobin Wu sold 6,725 shares of BeiGene stock in a transaction that occurred on Thursday, May 5th. The shares were sold at an average price of $164.35, for a total value of $1,105,253.75. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,712 shares of company stock worth $2,101,418. Corporate insiders own 8.90% of the company’s stock.

Shares of BGNE stock opened at $155.68 on Thursday. The firm has a market cap of $16.03 billion, a P/E ratio of -7.75 and a beta of 0.87. BeiGene, Ltd. has a fifty-two week low of $118.18 and a fifty-two week high of $426.56. The business’s 50 day moving average price is $147.39 and its 200-day moving average price is $198.61. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.87 and a current ratio of 5.05.

BeiGene (NASDAQ:BGNEGet Rating) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($4.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.52) by $0.28. The firm had revenue of $306.60 million for the quarter, compared to analyst estimates of $300.41 million. BeiGene had a negative return on equity of 40.10% and a negative net margin of 218.25%. BeiGene’s quarterly revenue was down 49.4% on a year-over-year basis. As a group, equities analysts predict that BeiGene, Ltd. will post -15.13 EPS for the current year.

BeiGene Profile (Get Rating)

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Recommended Stories

Institutional Ownership by Quarter for BeiGene (NASDAQ:BGNE)

Want More Great Investing Ideas?

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.